N. B. Leighl

991 total citations · 1 hit paper
32 papers, 758 citations indexed

About

N. B. Leighl is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, N. B. Leighl has authored 32 papers receiving a total of 758 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 17 papers in Oncology and 14 papers in Cancer Research. Recurrent topics in N. B. Leighl's work include Lung Cancer Treatments and Mutations (23 papers), Cancer Genomics and Diagnostics (10 papers) and Lung Cancer Diagnosis and Treatment (8 papers). N. B. Leighl is often cited by papers focused on Lung Cancer Treatments and Mutations (23 papers), Cancer Genomics and Diagnostics (10 papers) and Lung Cancer Diagnosis and Treatment (8 papers). N. B. Leighl collaborates with scholars based in United States, Canada and France. N. B. Leighl's co-authors include Rodryg Ramlau, Martin Reck, J. Mezger, Petr Zatloukal, Joachim von Pawel, Vera Hirsh, V. Gorbounova, Venice Archer, C. Manegold and Norman C. Moore and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

N. B. Leighl

29 papers receiving 736 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

2010 498 citations Martin Reck, Joachim von Pawel et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
N. B. Leighl United States	11	568	498	206	128	67	32	758
Osvaldo Rudy Aren Chile	12	647 1.1×	489 1.0×	310 1.5×	189 1.5×	78 1.2×	22	841
Rinat Galiulin United States	6	388 0.7×	370 0.7×	135 0.7×	110 0.9×	39 0.6×	7	556
Claudia-Nanette Gann Germany	4	537 0.9×	479 1.0×	227 1.1×	116 0.9×	60 0.9×	9	767
V. Gorbounova Russia	3	397 0.7×	359 0.7×	124 0.6×	95 0.7×	46 0.7×	7	516
K. Park South Korea	8	636 1.1×	529 1.1×	219 1.1×	123 1.0×	36 0.5×	25	714
Yoshiro Fujiwara Japan	16	592 1.0×	618 1.2×	220 1.1×	172 1.3×	36 0.5×	30	841
Sook Jung Jo South Korea	6	724 1.3×	692 1.4×	171 0.8×	112 0.9×	86 1.3×	8	865
Lilia Stelmakh Russia	4	1.1k 1.9×	935 1.9×	226 1.1×	159 1.2×	58 0.9×	8	1.2k
Werner Freier Germany	15	360 0.6×	513 1.0×	186 0.9×	129 1.0×	99 1.5×	28	760
Mark R. Olsen United States	12	591 1.0×	416 0.8×	257 1.2×	174 1.4×	31 0.5×	20	774

Countries citing papers authored by N. B. Leighl

Since Specialization

Citations

This map shows the geographic impact of N. B. Leighl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. B. Leighl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. B. Leighl more than expected).

Fields of papers citing papers by N. B. Leighl

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by N. B. Leighl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. B. Leighl. The network helps show where N. B. Leighl may publish in the future.

Co-authorship network of co-authors of N. B. Leighl

This figure shows the co-authorship network connecting the top 25 collaborators of N. B. Leighl. A scholar is included among the top collaborators of N. B. Leighl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with N. B. Leighl. N. B. Leighl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Leighl, N. B., Catherine A. Shu, Anna Minchom, et al.. (2021). 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study. Annals of Oncology. 32. S951–S952. 20 indexed citations

2.

Paudel, Bishnu Dutta, et al.. (2019). EP1.01-40 Outcome of EGFR-Mutated and Non-Mutated Lung Adenocarcinoma Receiving Standard Therapy - A Nepalese Cohort. Journal of Thoracic Oncology. 14(10). S927–S927.

3.

Stockley, Tracy, Ming‐Sound Tsao, Joshua C. Morganstein, et al.. (2018). P2.03-03 Upfront Next Generation Sequencing in NSCLC: A Publicly Funded Perspective. Journal of Thoracic Oncology. 13(10). S717–S717.

4.

Vincent, Mark, et al.. (2012). Biomarkers That Currently Affect Clinical Practice: EGFR, ALK, MET, KRAS. Current Oncology. 19(11). 33–44. 37 indexed citations

5.

Ng, D. C. K., et al.. (2012). Abstract P5-18-14: Cardiac monitoring during adjuvant trastuzumab therapy for breast cancer. Cancer Research. 72(24_Supplement). P5–18. 3 indexed citations

6.

Horgan, Anne M., Penelope A. Bradbury, Eitan Amir, et al.. (2011). An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Annals of Oncology. 22(8). 1805–1811. 21 indexed citations

7.

Hasani, Arman, et al.. (2011). Systemic therapy usage and outcomes for patients diagnosed with malignant pleural mesothelioma (MPM) between 2005 and 2010 in Ontario, Canada.. Journal of Clinical Oncology. 29(15_suppl). 7085–7085. 1 indexed citations

8.

Gu, Chu‐Shu, A. Sun, Robert M. MacRae, et al.. (2011). An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival.. Journal of Clinical Oncology. 29(15_suppl). 7018–7018. 11 indexed citations

9.

Campbell, Nicholas, Rangesh Kunnavakkam, N. B. Leighl, et al.. (2011). Cediranib (C) in patients (pts) with malignant mesothelioma (MM): A phase II trial of The University of Chicago Phase II Consortium.. Journal of Clinical Oncology. 29(15_suppl). 7027–7027. 2 indexed citations

10.

Lambrechts, Diether, Paul Delmar, D.W. Miles, et al.. (2011). 1414 POSTER Single Nucleotide Polymorphism Analysis and Outcome in Advanced-stage Cancer Patients Treated With Bevacizumab. European Journal of Cancer. 47. S173–S173. 9 indexed citations

11.

Wakelee, Heather A., Suzanne E. Dahlberg, S.M. Keller, et al.. (2011). Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 29(15_suppl). 7013–7013. 25 indexed citations

12.

Reck, Martin, Joachim von Pawel, Petr Zatloukal, et al.. (2010). Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology. 21(9). 1804–1809. 498 indexed citations breakdown →

13.

Leighl, N. B., Petr Zatloukal, J. Mezger, et al.. (2009). Efficacy and safety of first-line bevacizumab (Bv) and cisplatin/gemcitabine (CG) in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC) in the BO17704 study (AVAiL). Journal of Clinical Oncology. 27(15_suppl). 8050–8050. 15 indexed citations

14.

Jang, Raymond Woo-Jun, Pierre K. Isogai, R. P. Ng, et al.. (2008). PCN58 A COST UTILITY ANALYSIS OF ERLOTINIB IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC). Value in Health. 11(3). A72–A72. 4 indexed citations

15.

Leighl, N. B., et al.. (2006). PCN11 PHARMACOECONOMIC ANALYSES OF ERLOTINIB COMPARED WITH BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF RELAPSED NON-SMALL CELL LUNG CANCER (NSCLC) FROM THE CANADIAN PUBLIC HEALTH CARE PERSPECTIVE. Value in Health. 9(6). A279–A279. 10 indexed citations

16.

Hollen, Patricia J., Richard J. Gralla, John A. Stewart, et al.. (2005). A prospective comparison of Karnofsky (KPS) with ECOG performance status in patients with non-small cell lung cancer (NSCLC): A COMET group study investigating sensitivity and specificity issues important in clinical decision making. Journal of Clinical Oncology. 23(16_suppl). 8134–8134. 2 indexed citations

17.

Leighl, N. B., Scott A. Laurie, Jennifer J. Knox, et al.. (2005). Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors. Journal of Clinical Oncology. 23(16_suppl). 7253–7253. 2 indexed citations

18.

Leighl, N. B., Frances A. Shepherd, Luis Paz‐Ares, et al.. (2004). Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. Journal of Clinical Oncology. 22(14_suppl). 7038–7038. 2 indexed citations

19.

Leighl, N. B., Frances A. Shepherd, Luis Paz‐Ares, et al.. (2004). Randomized phase II-III study of matrix metalloproteinase inhibitor (MMPI) BMS-275291 in combination with paclitaxel (P) and carboplatin (C) in advanced non-small cell lung cancer (NSCLC): NCIC-CTG BR.18. Journal of Clinical Oncology. 22(14_suppl). 7038–7038. 6 indexed citations

20.

Jackson, David H., et al.. (2003). 769 Reducing health care burden for the treatment of toxicity associated with pemetrexed or docetaxel in patients with advanced non-small cell lung cancer who previously received chemotherapy: application to the UK setting. European Journal of Cancer Supplements. 1(5). S231–S231. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact